The Richmond Research Institute is an independent, academic research unit dedicated to understanding and improving the safety of pharmaceuticals.
Our world-class research aims to explore the usefulness of potential new medicines, assesses the safety of existing medicinal products, and provides the scientific insights to improve strategies for personalised medicines.
Our work helps scientists and regulators gain a mechanistic understanding of the effects of medicines to develop better and safer pharmaceutical products.
We take a mechanistic approach to test the impact of combinations of factors such as the co-administration of different drugs, food intake, co-morbidities and differences in sex and ethnic origin on drug safety. Clinical research trials assess the safety of an investigational medicinal product (IMP), however, this is often in isolation and the combined effects of other factors such as co-administration of prescription medications are not tested. This could potentially result in sudden cardiac death (SCD). Inadequacies in how the cause of death is diagnosed, recorded and the adverse reactions to drugs reported (on a voluntary basis) means information that could link the cause of a SCD as drug-induced is not accessible.
With access to state-of-art facilities at Richmond Pharmacology – a London-based research unit – we are committed to improving clinical trial designs for more efficient and rapid conclusion.
Our academic rigor to studying drug safety and drug interactions bridges the gap between industry and academia. In collaboration with St George’s University of London and other academic partners, we strive to overcome many of the challenges involved in medical and clinical research.
Committed to driving innovation whilst maintaining the highest ethical standards, our research helps to improve the health and safety of patients worldwide.
Meet our Scientific Experts
Learn more about the backgrounds and research interests of our key experts.Scientific Team